Blt potential, page-4

Alnylam is further down the road than Benitec, despite not having commercialized yet. However, in my opinion, if Alnylam has a similar approach in regards to RNAi and enjoys a robust mc, imagine the possibilities when you make that therapy more continuous with ddrnai. Additionally, I think a big hurdle is listing on a major exchange. I personally hope to see uplisting by the end of the year. I don't see why they couldn't if therapeutic response is demonstrated by Tt-034. The recent lung cancer data that extended to pancreatic and kidney only add to more indications. Benitec really needs to get Tribetarna moving soon. I would also like to see more significant movement on the Hep B area as well. I think if we have those two moving forward in significant ways this year, I believe we will see a drastic bump in mc. But listing on a major US exchange as an integral part of that though. Just my opinion.